002566.SZ(002566.SZ)
002566.SZ
$7.02—Stale · unknown old
SHZ • Last print unknown ago
$7.02—Stale · unknown old
Jilin Jian Yisheng Pharmaceutical Co., Ltd. specializes in the research, development, and production of biopharmaceuticals, particularly focusing on innovative therapies for chronic diseases. The company has a strong presence in China, leveraging its high gross margins of 74% to maintain a competitive edge in the biotechnology sector.
The company generates revenue primarily through the sale of its proprietary biopharmaceutical products, which are priced at a premium due to their innovative nature and effectiveness. Its competitive advantages include a strong R&D pipeline and established relationships with healthcare providers in China.
Regulatory approvals for new drugs
Partnerships with larger pharmaceutical companies
Market demand for chronic disease therapies
Changes in healthcare policy in China
Regulatory changes impacting drug approvals
Technological disruption in biopharmaceuticals
Emergence of generic competitors
Increased R&D spending by larger pharmaceutical firms
Low ROE (1.5%) indicating potential inefficiencies
Limited cash flow growth despite high gross margins
moderate - The biotechnology sector is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by GDP fluctuations.
The company's low debt levels (Debt/Equity of 0.21) mean that rising interest rates have minimal impact on financing costs, but they could affect overall market valuations.
minimal - The company does not rely heavily on credit for operations.
growth - Investors are likely attracted to the potential for high returns from innovative biopharmaceutical products.
high - The stock has shown significant volatility with a 1-year return of -26.5%.